Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has lost 1.67% to settle at $9.98 with a volume of 118,000 shares. For the past 52 weeks the stock has been trading between $8.79 and $18.85 with an average volume of 297,000 shares. Company has a market cap of 422 million shares and trades with an average beta of 0.81.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing therapeutics based on ribonucleic acid interface (RNAi). The RNAi therapeutic program, ALN-RSV01, is in Phase II clinical trials for the treatment of human respiratory syncytial virus (RSV), infection. In February 2008, the Company reported the positive results from the Phase II experimental RSV infection clinical trial, referred to as the GEMINI study. In July 2009 the Company and Cubist Pharmaceuticals, Inc. (Cubist) reported results from a Phase IIa clinical trial assessing the safety and tolerability of aerosolized ALN-RSV01 versus placebo in adult lung transplant patients naturally infected with RSV.
Velti Plc (NASDAQ:VELT) has gained 3.7% to settle at $12.61 with a volume of 571,000 shares. For the past 52 weeks the stock has been trading between $4.55 and $15.89 with an average volume of 725,000 shares. Company has a market cap of $456 million.
Velti plc (Velti) is a global provider of mobile marketing and advertising solutions that enable brands, advertising agencies, mobile operators and media companies to implement campaigns by communicating with and engaging consumers through their mobile devices. During the year ended December 31, 2009, over 450 brands, advertising agencies, mobile operators and media companies used its solution to conduct over 2,000 campaigns.
Winnebago Industries (NYSE:WGO) lost 12.5% to settle at $13.29 with a volume of 1.4 million shares. For the past 52 weeks the stock has been trading between $8.10 and $17.43 with an average volume of 334,000 shares. Company has a market cap of $387 million and trades with an average beta of 2.43.
Winnebago Industries, Inc. (Winnebago Industries) is the United States manufacturer of motor homes, which are self-contained recreation vehicles (RV) used primarily in leisure travel and outdoor recreation activities. It sells motor homes through independent dealers under the Winnebago, Itasca and ERA brand names. Other products manufactured by Winnebago Industries consist primarily of original equipment manufacturing (OEM) parts, including extruded aluminum and other component products for other manufacturers and commercial vehicles.its
Hitachi (NYSE:HIT) has gained 2.04% to settle at $50.43 with a total traded volume of 256,000 shares. For the past 52 weeks the stock has been trading between $35 and $65.29 with an average volume of 204,000 shares. Company has a market cap of $22.77 billion and trades with an average beta of 1.70.
Hitachi, Ltd. (Hitachi) is engaged in developing a diversified product mix ranging from electricity generation systems to consumer products and electronic devices. The Company operates in 11 segments: Information & Telecommunication Systems, which includes systems integration, outsourcing services and automated teller machines (ATMs); Power Systems, which includes thermal, nuclear and wind power generation systems; Social Infrastructure & Industrial System, which includes industrial machinery and plants, elevators systems; Electronic Systems & Equipment; Construction Machinery; High Functional Materials & Components, which includes wires and cables, copper products and materials; Automotive Systems; Components & Devices; Digital Media & Consumer Products; Financial Services and Others.
BioSante (NASDAQ:BPAX) gained 2.19% to settle at $1.87 with a total traded volume of 738,000 shares. For the past 52 weeks the stock has been trading between $1.29 and $2.54 with an average volume of 2.18 million shares. Company has a market cap of $133 million and trades with a beta of 1.14.
BioSante Pharmaceuticals, Inc. (BioSante) is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. The Company's products for female sexual health, menopause, contraception and male hypogonadism include LibiGel, a once daily transdermal testosterone gel in Phase III clinical development under a special protocol assessment (SPA) for the treatment of female sexual dysfunction (FSD); Elestrin, a once daily transdermal estradiol (estrogen) gel indicated for the treatment of moderate-to-severe vasomotor symptoms; The Pill-Plus (triple component contraceptive), a once daily use of various combinations of estrogens, progestogens and androgens in development for the treatment of female sexual dysfunction (FSD) in women using oral or transdermal contraceptives, and Bio-T-Gel, a once daily transdermal testosterone gel in development for the treatment of hypogonadism, or testosterone deficiency, in men.
OTCPicks.com is not a registered investment advisers or broker/dealer. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market their securities, investing in such securities is highly speculative and carries a high degree of risk. Always do you own homework before investing in any stock.
Forward-Looking Statement: This press release includes "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.
Disclosure: OTCpicks.com has not been compensated for any current or recent stocks listed in this stock news report
